Chlorhexidine gluconate 0.2% as a treatment for recalcitrant fungal keratitis in Uganda: a pilot study.
cornea
epidemiology
infection
microbiology
public health
Journal
BMJ open ophthalmology
ISSN: 2397-3269
Titre abrégé: BMJ Open Ophthalmol
Pays: England
ID NLM: 101714806
Informations de publication
Date de publication:
2021
2021
Historique:
received:
19
01
2021
accepted:
27
06
2021
entrez:
9
8
2021
pubmed:
10
8
2021
medline:
10
8
2021
Statut:
epublish
Résumé
Fungal keratitis is a major ophthalmic public health problem, particularly in low-income and middle-income countries. The options for treating fungal keratitis are limited. Our study aimed to describe the outcomes of using chlorhexidine 0.2% eye-drops as additional treatment in the management of patients with recalcitrant fungal keratitis. This study was nested within a large cohort study of people presenting with microbial keratitis in Uganda. We enrolled patients with recalcitrant fungal keratitis not improving with topical natamycin 5% and commenced chlorhexidine 0.2%. Follow-up was scheduled for 3 months and 1 year. The main outcome measures were healing, visual acuity and scar size at final follow-up. Thirteen patients were followed in this substudy. The patients were aged 27-73 years (median 43 years). Filamentous fungi were identified by microscopy of corneal scrape samples in all cases. Isolated organisms included Chlorhexidine 0.2% was found to be a useful sequential adjunctive topical antifungal in cases of fungal keratitis not responding to natamycin 5%, which warrants further evaluation.
Identifiants
pubmed: 34368461
doi: 10.1136/bmjophth-2020-000698
pii: bmjophth-2020-000698
pmc: PMC8258663
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e000698Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Br J Ophthalmol. 1998 Aug;82(8):919-25
pubmed: 9828778
Ophthalmic Epidemiol. 2020 Apr;27(2):121-131
pubmed: 31830848
Oral Dis. 2017 Jul;23(5):598-608
pubmed: 27479137
Cochrane Database Syst Rev. 2015 Apr 09;(4):CD004241
pubmed: 25855311
Ophthalmic Epidemiol. 1997 Sep;4(3):141-9
pubmed: 9377282
Ophthalmic Epidemiol. 2011 Aug;18(4):158-63
pubmed: 21780874
Clin Microbiol Rev. 1999 Jan;12(1):147-79
pubmed: 9880479
Eye (Lond). 1996;10 ( Pt 4):413-21
pubmed: 8944089
JAMA Ophthalmol. 2016 Dec 1;134(12):1365-1372
pubmed: 27787540
Anaesth Intensive Care. 2008 Jul;36(4):502-12
pubmed: 18714617
Ophthalmology. 1999 Apr;106(4):798-802
pubmed: 10201605
Ophthalmology. 2014 Aug;121(8):1495-500.e1
pubmed: 24746358
BMC Microbiol. 2020 Sep 5;20(1):275
pubmed: 32891143
Public Health. 2016 Oct;139:27-35
pubmed: 27311991
Cornea. 2012 Apr;31(4):371-5
pubmed: 22262225
Br J Ophthalmol. 2006 Jun;90(6):686-9
pubmed: 16531425
JAMA Ophthalmol. 2016 Dec 1;134(12):1372-1373
pubmed: 27787542
Antimicrob Agents Chemother. 2019 Jul 25;63(8):
pubmed: 31182529
Am J Ophthalmol. 2016 Aug;168:227-236
pubmed: 27287820
J Ocul Pharmacol Ther. 2013 Mar;29(2):270-4
pubmed: 23410063
Lancet Glob Health. 2019 Dec;7(12):e1612-e1613
pubmed: 31606327
Br J Ophthalmol. 2005 Dec;89(12):1554-8
pubmed: 16299128
Br J Ophthalmol. 1995 Nov;79(11):1024-8
pubmed: 8534648
Am J Ophthalmol. 2009 Oct;148(4):487-499.e2
pubmed: 19660733
Med Mycol Case Rep. 2018 Jul 17;22:14-17
pubmed: 30094132
Br J Ophthalmol. 2002 Nov;86(11):1211-5
pubmed: 12386069
JAMA Ophthalmol. 2013 Apr;131(4):422-9
pubmed: 23710492
Eur J Ophthalmol. 2003 Jan-Feb;13(1):11-7
pubmed: 12635669
JAMA Ophthalmol. 2015 Aug;133(8):930-7
pubmed: 26022921
Br J Ophthalmol. 1997 Aug;81(8):622-3
pubmed: 9349145
Arch Ophthalmol. 2010 Jun;128(6):672-8
pubmed: 20547942
Clin Exp Ophthalmol. 2011 Jul;39(5):434-40
pubmed: 21105974
J Fungi (Basel). 2021 Mar 29;7(4):
pubmed: 33805369
J Fungi (Basel). 2017 Oct 18;3(4):
pubmed: 29371573
Br J Ophthalmol. 2015 Sep;99(9):1190-5
pubmed: 25740805